Featured Publications
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughtsA systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors
2023
Characteristics of trichotillomania and excoriation disorder across the lifespan
Lin A, Farhat L, Flores J, Levine J, Fernandez T, Bloch M, Olfson E. Characteristics of trichotillomania and excoriation disorder across the lifespan. Psychiatry Research 2023, 322: 115120. PMID: 36842397, PMCID: PMC10023474, DOI: 10.1016/j.psychres.2023.115120.Peer-Reviewed Original ResearchConceptsExcoriation disorderClinical characteristicsSkin-picking severityAttention-deficit/hyperactivity disorderCo-occurring conditionsBody-focused repetitive behaviorsObsessive-compulsive disorderSeverity scoreCurrent symptomsSignificant positive correlationTrichotillomaniaHyperactivity disorderDisordersSelf-reported anxietyAge 4High rateSubtypesSelf-report measuresSeverityCross-sectional survey responsesRepetitive behaviorsAdulthoodPositive correlation
2022
Parental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis
Polga N, de Barros P, Farhat LC, de Almeida K, Bloch MH, Lafer B. Parental age and the risk of bipolar disorder in the offspring: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica 2022, 145: 568-577. PMID: 35188977, DOI: 10.1111/acps.13418.Peer-Reviewed Original ResearchConceptsRisk of BDBipolar disorderMaternal ageOdds ratioParental ageReference categoryOlder maternal age groupsAge groupsPaternal age groupsMaternal age groupsWeb of ScienceObservational studySystematic reviewAgeFurther studiesRiskDisordersOffspringAssociationEffect size indexEMBASEGroupSize indexPubMedStudy
2019
The impact of attention deficit hyperactivity disorder in obsessive‐compulsive disorder subjects
Blanco‐Vieira T, Santos M, Ferrão YA, Torres AR, Miguel EC, Bloch MH, Leckman JF, do Rosario MC. The impact of attention deficit hyperactivity disorder in obsessive‐compulsive disorder subjects. Depression And Anxiety 2019, 36: 533-542. PMID: 30990937, DOI: 10.1002/da.22898.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderAdult OCD patientsObsessive-compulsive disorderDeficit hyperactivity disorderOCD patientsClinical characteristicsExact testFeatures of ADHDHyperactivity disorderSubgroup of patientsAdult obsessive-compulsive disorderComorbid attention deficit hyperactivity disorderSpecific clinical featuresCross-sectional studyObsessive-compulsive disorder (OCD) subjectsLogistic regression analysisFisher's exact testBrazilian Research ConsortiumMann-Whitney testAdult patientsRheumatic feverDevelopment of interventionsClinical featuresObsessive-compulsive spectrum disordersLifetime prevalence
2018
Time course of clinical change following neurofeedback
Rance M, Walsh C, Sukhodolsky DG, Pittman B, Qiu M, Kichuk SA, Wasylink S, Koller WN, Bloch M, Gruner P, Scheinost D, Pittenger C, Hampson M. Time course of clinical change following neurofeedback. NeuroImage 2018, 181: 807-813. PMID: 29729393, PMCID: PMC6454268, DOI: 10.1016/j.neuroimage.2018.05.001.Peer-Reviewed Original ResearchConceptsClinical changesSymptom changeTime courseBrain functionNeurofeedback studiesPotential clinical toolCrossover designControl interventionsReal neurofeedbackClinical toolTime pointsClinical populationsNeurofeedback effectsInterventionNeurofeedback sessionsNeurofeedbackCurrent brain stateWeeksBrain statesNew studiesCourseSessionsSymptoms
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG, Jakubovski E, Bloch MH. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. The Journal Of Clinical Psychiatry 2016, 77: e1262-e1269. PMID: 27631142, DOI: 10.4088/jcp.15m10075.Peer-Reviewed Original ResearchConceptsMajor depressive disorderCitalopram treatmentSuicidal ideationClinical predictorsClinical variablesSelective serotonin reuptake inhibitorsNonpsychotic major depressive disorderFirst-line treatmentBaseline clinical variablesSerotonin reuptake inhibitorsWeeks of treatmentSequenced Treatment AlternativesSide effect dataGreater likelihoodTime coursePhase 1Cardiac comorbiditiesNeurologic comorbiditiesBaseline characteristicsSedative medicationsReuptake inhibitorsTrial phase 1Clinical correlatesQuick InventoryDepressive disorder
2015
Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial
Jakubovski E, Bloch MH. Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial. Psychiatric Quarterly 2015, 87: 445-464. PMID: 26563229, DOI: 10.1007/s11126-015-9399-6.Peer-Reviewed Original ResearchConceptsSocial anxiety disorderAnxiety disordersCoordinated Anxiety LearningAnxiety LearningPost-traumatic stress disorderSelf-efficacy expectanciesPositive treatment expectanciesGeneralized anxiety disorderTreatment outcomesStress disorderTreatment expectanciesSpecific treatment needsSocial supportPanic disorderDisordersLearningSocioeconomic statusPredictorsPrognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome ScaleRiluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal Of Clinical Psychiatry 2015, 76: 1075-84. PMID: 26214725, PMCID: PMC4560666, DOI: 10.4088/jcp.14m09123.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialObsessive-compulsive disorderSmall open-label trialsTreatment-refractory obsessive-compulsive disorderGlutamate modulator riluzoleSignificant residual symptomsOpen-label trialSubset of patientsDSM-IV obsessive-compulsive disorderBest available treatmentsPlacebo leadRiluzole groupRefractory symptomsPartial responseSignificant morbidityResidual symptomsModerate nauseaAvailable treatmentsStandard interventionGlutamate homeostasisRiluzoleSide effectsSRI treatmentPatientsSecondary analysisPredictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial
Taylor JH, Jakubovski E, Bloch MH. Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial. Journal Of Psychiatric Research 2015, 65: 154-165. PMID: 25896121, PMCID: PMC4492801, DOI: 10.1016/j.jpsychires.2015.03.020.Peer-Reviewed Original ResearchConceptsCoordinated Anxiety LearningAnxiety recurrenceAnxiety LearningAnxiety Sensitivity Index scoreUsual careCognitive behavioral therapyRelapse prevention programAnxiety remissionBehavioral therapyAnxiety disordersMultivariable logistic regression modelResidual anxietyCollaborative care interventionPrimary care clinicsPrimary care settingRisk of recurrenceComorbid depressionManagement trialsReceiver Operating CharacteristicLogistic regression modelsMonth 6Care clinicsPrevention programsPrognostic subgroupsCare interventions
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomesPrognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroupsHistidine Decarboxylase Deficiency Causes Tourette Syndrome: Parallel Findings in Humans and Mice
Baldan LC, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C. Histidine Decarboxylase Deficiency Causes Tourette Syndrome: Parallel Findings in Humans and Mice. Neuron 2014, 81: 77-90. PMID: 24411733, PMCID: PMC3894588, DOI: 10.1016/j.neuron.2013.10.052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmphetamineAnimalsBrainChildDopamine AgonistsDopamine AntagonistsExploratory BehaviorFemaleHistidine DecarboxylaseHumansMaleMaze LearningMiceMice, KnockoutMiddle AgedMutationOxazinesRacloprideRadionuclide ImagingStereotyped BehaviorTime FactorsTourette SyndromeTryptophanYoung AdultConceptsTourette syndromeHA infusionKnockout miceD2/D3 receptor bindingDecarboxylase deficiencyDopamine D2 antagonist haloperidolCortico-basal ganglia circuitsStriatal DA levelsHDC knockout miceD3 receptor bindingImmediate early gene FosD2 antagonist haloperidolRare genetic causeBiosynthesis of histamineStriatal DARare causeBasal gangliaDA levelsAntagonist haloperidolGanglia circuitsPrepulse inhibitionMiceReceptor bindingGenetic causeHistidine decarboxylase
2013
Global Resting-State Functional Magnetic Resonance Imaging Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-Compulsive Disorder
Anticevic A, Hu S, Zhang S, Savic A, Billingslea E, Wasylink S, Repovs G, Cole MW, Bednarski S, Krystal JH, Bloch MH, Li CS, Pittenger C. Global Resting-State Functional Magnetic Resonance Imaging Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-Compulsive Disorder. Biological Psychiatry 2013, 75: 595-605. PMID: 24314349, PMCID: PMC3969771, DOI: 10.1016/j.biopsych.2013.10.021.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPrefrontal cortexResting-state functional connectivity dataStriatum/nucleus accumbensVentral striatum/nucleus accumbensResting-state functional connectivity studiesVentral anterior cingulate cortexCortico-striatal circuitsMagnetic Resonance Imaging AnalysisAnterior cingulate cortexFunctional connectivity studiesBasal gangliaControl subjectsFunctional connectivity dataAnterior thalamusRight putamenFrontal cortexNucleus accumbensDorsal striatumCerebellar cortexAbnormal neural connectivityCerebellar dysconnectivityCingulate cortexWhole brainFunctional magnetic resonance imaging (fMRI) analysisBrain mechanisms for prepulse inhibition in adults with Tourette syndrome: Initial findings
Zebardast N, Crowley MJ, Bloch MH, Mayes LC, Wyk BV, Leckman JF, Pelphrey KA, Swain JE. Brain mechanisms for prepulse inhibition in adults with Tourette syndrome: Initial findings. Psychiatry Research 2013, 214: 33-41. PMID: 23916249, PMCID: PMC3932431, DOI: 10.1016/j.pscychresns.2013.05.009.Peer-Reviewed Original ResearchConceptsTourette syndromeFunctional magnetic resonance imagingHealthy subjectsTic severityWhole-brain functional magnetic resonance imagingYale Global Tic Severity ScaleTactile startle responseCase-control study designTic Severity ScaleCortical-striatal circuitsBrain activityMagnetic resonance imagingMultiple brain regionsLeft middle frontal gyrusMiddle frontal gyrusDegree of PPIPulse-alone stimuliBlock-design fMRI paradigmTic symptomsNeuropathological dataHealthy controlsPrepulse inhibitionDevelopmental neuropsychiatric disordersSensorimotor gatingLeft caudateTwo cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder
Niciu MJ, Grunschel B, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. Journal Of Psychopharmacology 2013, 27: 651-654. PMID: 23676198, DOI: 10.1177/0269881113486718.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAntidepressant effectsPsychiatric comorbidityComorbid depressionNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistTreatment-refractory obsessive-compulsive disorderAcute antidepressant effectsTreatment-resistant unipolarOpen-label trialSevere respiratory depressionAdverse neuropsychiatric effectsComorbid psychiatric disordersMinimal depressive symptomsOff-label useMajor depressive disorderStart of infusionRespiratory depressionIntravenous ketamineNeuropsychiatric effectsKetamine infusionBipolar depressionReceptor antagonistDepressive disorderSedative effectsLONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitorsSymptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder
Kichuk SA, Torres AR, Fontenelle LF, Rosário MC, Shavitt RG, Miguel EC, Pittenger C, Bloch MH. Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 44: 233-239. PMID: 23410525, PMCID: PMC3654083, DOI: 10.1016/j.pnpbp.2013.02.003.Peer-Reviewed Original ResearchConceptsAge of onsetClinical courseObsessive-compulsive disorderPrimary symptom dimensionsSymptom dimensionsPrimary OCD symptomsChi-square testEarly ageOCD symptom dimensionsYale-Brown ObsessiveAdult patientsComorbid ticsSignificant symptomsLarge cohortDifferent OCD symptom dimensionsHeterogeneous symptomsSymptomsCompulsive ScaleDimensional Yale-Brown ObsessiveAgeSignificant differencesOCD symptomsOnsetInconsistent results